|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Diethylstilbestrol as a "morning-after" contraceptive. |
| Medical Letter on Drugs and Therapeutics 15(14): 58-59. July 6, 1973. |
| Diethylstilbestrol (DES) is a nonsteroidal synthetic estrogen. It has been approved as a "morning-after" contraceptive. |
| It is thought to interfere with the implantation of the fertilized ovum. Among 5593 women treated with DES or other |
| estrogens, 26 pregnancies have been reported. Most of these patients reported midcycle exposures. Of 92 patients |
| with adenocarcinoma of the vagina or cervix, prenatal histories of 66 were obtained. The mothers of 49 of them had |
| taken DES or related nonsteroidal estrogens during pregnancy. In 1 case the mother had received only 1.5 mg daily. |
| Another mother was treated for only 5 days during the first trimester. There is no evidence that the use of DES |
| increases the risk of cancer in the mother. The Food and Drug Administration has approved the use of DES as an |
| emergency treatment only. Early therapeutic abortion is recommended when this use of DES fails, because of the |
| possibility of a teratogenic effect. The recommended oral dosage is 25 mg twice daily for 5 consecutive days, begun |
| within 72 hours after sexual exposure. Severe nausea and vomiting may occur. Headaches and menstrual |
| irregularities have also been reported. (PubHealth.info Document ID: CONT8T 536-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Diethylstilbestrol as a "morning-after" contraceptive.", |
| is(are) . The source of this article is "Medical Letter on Drugs and Therapeutics 15(14): 58-59. July 6, 1973.". This |
| article was published in 1973 in English language(s). (PubHealth.info® Document ID: CONT8T 536-06. All rights |
| reserved with PubHealth.info) PIN: 35536 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |